The infliximab therapy was prematurely stopped in three patients (12.5%) between the three- and six months follow-up period due to one patient with a severe allergic reaction (itching, rash, and shortness of breath during the infusion), one patient with a significant rise in liver enzymes (ALT and AST more than 10 times of the normal), and one patient with insurance coverage problems (Figure 1). Here, GPT is linked to allergic disease.